Debieuvre Didier, Locher Chrystèle, Asselain Bernard, Dayen Charles, Molinier Olivier, Falchero Lionel, Dujon Cécile, Delclaux Bertrand, Grivaux Michel
Groupe hospitalier de la région Mulhouse Sud-Alsace, hôpital Emile Muller, respiratory medicine department, 20, avenue du Dr Laënnec, BP 1370, 68070 Mulhouse cedex, France.
Hôpital de Meaux, respiratory medicine department, 6-8, rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France.
Bull Cancer. 2019 Apr;106(4):283-292. doi: 10.1016/j.bulcan.2019.01.010. Epub 2019 Feb 23.
Although improved during the last decades, the prognosis of lung cancer is poor. In 2000, the French College of general hospital respiratory physicians, conducted KBP-2000-CPHG, a prospective multicenter epidemiological study including all volunteer adult patients diagnosed for primary lung cancer; with the five-year survival as primary endpoint. The primary objective of KBP-2010-CPHG was to compare overall five-year survival data with KBP-2000-CPHG ones.
All consecutive patients≥18 years of age with primary lung cancer diagnosed between 1st January and 31st December 2010 were included. The KBP-2010-CPHG protocol was approved by the advisory committee on research information processing in the health field (CCTIRS) on November 19, 2009.
Respectively, 5667 and 7051 patients were included in KBP-2000-CPHG and KBP-2010-CPHG. Five-year survival was improved: 12.7% [11.9%-13.5%] in 2010 versus 10.0% [9.2%-10.9%] in 2000 (P<0.001). Non-small-cell lung cancer showed improvement (13.8% [13.0%-14.8%] in 2010 versus 11.4% [10.5%-12.4%] in 2000; P<0.001); but not small-cell lung cancer (5.7% [4.4%-7.4%] in 2010 versus 3.3% [2.3%-4.7%] in 2000; P=0.56). The KBP-2010-CPHG study showed an overall 6% reduction in risk of death (HR=0.94 [0.89-0.98]; P=0.004).
Survival of patients with lung cancer improved over a 10-year period. This improvement was slight and limited to non-small-cell lung cancer, possibly partly because of 2010 advances in diagnosis and targeted therapy.
尽管在过去几十年中有所改善,但肺癌的预后仍然很差。2000年,法国综合医院呼吸内科医师学会开展了KBP - 2000 - CPHG研究,这是一项前瞻性多中心流行病学研究,纳入了所有自愿参与的成年原发性肺癌患者;以五年生存率作为主要终点。KBP - 2010 - CPHG的主要目标是将总体五年生存数据与KBP - 2000 - CPHG的数据进行比较。
纳入2010年1月1日至12月31日期间确诊的所有年龄≥18岁的原发性肺癌连续患者。KBP - 2010 - CPHG方案于2009年11月19日获得健康领域研究信息处理咨询委员会(CCTIRS)的批准。
KBP - 2000 - CPHG和KBP - 2010 - CPHG分别纳入了5667例和7051例患者。五年生存率有所提高:2010年为12.7%[11.9% - 13.5%],2000年为10.0%[9.2% - 10.9%](P<0.001)。非小细胞肺癌有改善(2010年为13.8%[13.0% - 14.8%],2000年为11.4%[10.5% - 12.4%];P<0.001);但小细胞肺癌没有改善(2010年为5.7%[4.4% - 7.4%],2000年为3.3%[2.3% - 4.7%];P = 0.56)。KBP - 2010 - CPHG研究显示总体死亡风险降低了6%(HR = 0.94[0.89 - 0.98];P = 0.004)。
肺癌患者的生存率在10年期间有所提高。这种改善很轻微,且仅限于非小细胞肺癌,可能部分归因于2010年诊断和靶向治疗方面的进展。